SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-10.11
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/ex10-11.htm

Chunk 2 of 3
Word Count: 295
Character Count: 1915

Document Content:

or regulations in effect in either of the United States or (b) would have the affect of causing the Company to be in violation of any laws, decrees, rules or regulations in effect in either of the United States. Notices. Any notices under this Agreement will be sent by certified or registered mail, return receipt requested, to the address specified below or such other address as the party specifies in writing. Such notice will be effective upon its mailing as specified. Complete Understanding; Modification. This Agreement, together with each version of Exhibit A executed by the parties, constitutes the complete and exclusive understanding and agreement of the parties and supersedes all prior understandings and agreements, whether written or oral, with respect to the subject matter hereof. Any waiver, modification or amendment of any provision of this Agreement will be effective only if in writing and signed by the parties hereto.

WITNESS WHEREOF, the parties have signed this Agreement as of the Effective Date.

BioVentrix,
Inc.: CONSULTANT:

By: Ori
Ben-Yehuda M.D.

James
Dillon

President
and Chief Executive Officer

Alcosta Blvd., Suite 400 Ori
Ben-Yehuda Consulting LLC

San
Ramon, CA 94583 44 Oak
Road

Katonah,

EXHIBIT

PROJECT
DESCRIPTION

This
Project Description is issued under and subject to all of the terms and conditions of the Consulting Agreement dated as of September
20, 2022 by and between BioVentrix, Inc. (the “Company”) and Ori Ben-Yehuda
M.D. (“Consultant”).

Services:
Medical and Clinical Advisory Services as requested by the Company from time to time.

Rate of Pay: $500 per hour plus all reasonable
pre-approved out -of -pocket expenses, including travel.

Invoicing: Monthly by the fifth business day of the following month

AGREED
AS OF September 20, 2022

BioVentrix,
Inc.:

James
Dillon

Its:	President
and Chief Executive Officer

CONSULTANT:

Ori
Ben-Yehuda M.D.